GFP
NVO

Gryphon Financial Partners’s Novo Nordisk NVO Stock Holding History

Gryphon Financial Partners’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,142
Closed -$285K – 344
2025
Q3 		$285K Sell
5,142
-61
-1% -$3.57K 0.03% 269
2025
Q2 		$359K Buy
5,203
+772
+17% +$52.5K 0.05% 226
2025
Q1 		$308K Buy
4,431
+1,045
+31% +$86.3K 0.04% 214
2024
Q4 		$291K Buy
3,386
+61
+2% +$6.6K 0.04% 213
2024
Q3 		$396K Buy
3,325
+239
+8% +$31.9K 0.05% 195
2024
Q2 		$440K Buy
3,086
+1,116
+57% +$148K 0.07% 178
2024
Q1 		$253K Sell
1,970
-324
-14% -$38.6K 0.04% 227
2023
Q4 		$237K Buy
+2,294
New +$227K 0.04% 209
2018
Q3 		– Sell
-426
Closed -$9K – 619
2018
Q2 		$9K Hold
426
– – ﹤0.01% 538
2018
Q1 		$11K Sell
426
-222
-34% -$5.83K 0.01% 505
2017
Q4 		$18K Buy
+648
New +$16.5K 0.01% 421

Other funds holding NVO

Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Gryphon Financial Partners's NVO Position: Q4 2025 in Review

Gryphon Financial Partners sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 5,142 shares — an estimated $285K sold.

Gryphon Financial Partners first reported a position in NVO in Q4 2017 and held it in 11 quarters. The position peaked at $440K in Q2 2024. 1,418 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

  • Gryphon Financial Partners reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
  • Gryphon Financial Partners sold 5,142 Novo Nordisk shares in Q4 2025, an estimated $285K.
  • Gryphon Financial Partners first reported a position in Novo Nordisk in Q4 2017 and held it in 11 quarters.
  • Gryphon Financial Partners's Novo Nordisk position peaked at $440K in Q2 2024.
  • 1,418 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Gryphon Financial Partners's 13F filing for Q4 2025, filed 8 Jan 2026.